You may also opt to downgrade to Standard Digital, a robust journalistic offering that fulfils many user’s needs. If you’d like to retain your premium access and save 20%, you can opt to pay annually at the end of the trial. If you do nothing, you will be auto-enrolled in our premium digital monthly subscription plan and retain complete access for $69 per month.įor cost savings, you can change your plan at any time online in the “Settings & Account” section. For a full comparison of Standard and Premium Digital, click here.Ĭhange the plan you will roll onto at any time during your trial by visiting the “Settings & Account” section. Premium Digital includes access to our premier business column, Lex, as well as 15 curated newsletters covering key business themes with original, in-depth reporting. Standard Digital includes access to a wealth of global news, analysis and expert opinion. Chinese medical data startup LinkDoc Technology is planning to raise 500 million in an initial public offering (IPO), Bloomberg reported, citing sources.During your trial you will have complete digital access to FT.com with everything in both of our Standard Digital and Premium Digital packages. LinkDoc’s IPO delay also comes as regulators in Beijing are planning rule changes that would allow them to block a Chinese company from listing overseas even if the unit selling shares is incorporated outside China, closing a loophole long-used by the country’s technology giants, Bloomberg News reported this week. Reuters reported LinkDoc’s IPO halt earlier Thursday. For the same period, net loss attributable to LinkDoc widened to 135.4 million renminbi (21.17 million) from 61.6 million renminbi a year earlier. LinkDoc Technology 859 followers on LinkedIn. The company’s listing plans come despite the U.S.Ī representative for LinkDoc declined to comment. initial public offering, people familiar with the matter said, the first known company to pull out of a debut after China. We are leading oncology real world big data company from China with the vision of care data and care life. HONG KONG Chinese medical data group LinkDoc Technology Ltd has shelved its listing in the United States to raise up to 211 million following Beijing’s clampdown on overseas listings, according to three sources with direct knowledge of the matter. LinkDoc, founded in 2014, provides cancer focused health-care services built on big data and artificial intelligence, its website shows. The LinkDoc Technology (hereinafter 'LinkDoc') case was compiled as one way to find answers to these questions. LinkDoc’s IPO delay also comes as regulators in Beijing are planning rule changes that would allow them to block a Chinese. Its investors include Alibaba Health Information Technology Ltd., MBK Partners, New Enterprise Associates and Temasek Holdings Pte according to a preliminary filing.Ĭhinese companies have raised about $13 billion through first-time share sales in the U.S. The case examines how LinkDoc, specializing in big data and serving the vertical healthcare industry, found its own answers to these issues and, more specifically, how it identified and entered its target market segment, and. this year, according to data compiled by Bloomberg. HONG KONG (Reuters) -Chinese medical data group LinkDoc Technology Ltd has shelved plans for an IPO in the United States due to Beijing's clampdown on overseas listings by domestic firms, according to three sources with direct knowledge of the matter. listing by a Chinese firm on record, after Alibaba Group Holding Ltd.’s $25 billion blockbuster debut in 2014. It is the first Chinese firm known to have pulled back from IPO plans since China's cybersecurity regulator toughened its approach to oversight.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |